# ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)

> **NCT07253324** · PHASE1 · COMPLETED · sponsor: **Engrail Therapeutics INC** · enrollment: 48 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** ENX-104
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07253324
- **Lead sponsor:** Engrail Therapeutics INC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-02-17
- **Primary completion:** 2025-11-26
- **Final completion:** 2025-11-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07253324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07253324, "ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07253324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*